The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.

We are pleased to partner with the Cancer Research Society (CRS) to co-fund 15 Operating Grants this funding cycle. The CRS is a national not-for-profit organization whose sole mission is to fund research on all types of cancer, thereby contributing to the advancement of science aimed at preventing, detecting, and treating the disease.

New this year, the LLSC is pleased to announce a research funding partnership with Waldenstrom’s Macroglobulemia Foundation of Canada to fund 1 grant in this competition. The Waldenstrom’s Macroglobulinemia Foundation of Canada (WMFC) supports Canadians with WM, and their families, by offering a range of services that can enhance quality of life for those with WM and funding research to ultimately discover a cure. WM applications should address signaling, immunology/immunotherapy, tumor microenvironment, “Omics”, or IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).